InvestorsHub Logo
Followers 0
Posts 80
Boards Moderated 0
Alias Born 07/27/2005

Re: None

Friday, 08/30/2019 7:46:58 AM

Friday, August 30, 2019 7:46:58 AM

Post# of 1121
What will be ACST patient population? They can't compete with AMRN on under 500 TG levels since they have no trial for that, so maybe just the smaller 500-1,500 hyperTrig population of the Trilogy trials? However they probably won't be best in class since they don't have outcomes trial whereas Vascepa proved to reduce cadio events. Right?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACST News